Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer
Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.
Foundation Medicine's ctDNA assay was able to subclassify patients into higher and lower recurrence risk groups with CTCs providing an additional boost.
In a study involving 250 military veterans, researchers have reported identifying and testing gene expression biomarkers whose levels rise with human stress.
Researchers developing the gene expression-based test say it could bring objectivity to a subjective diagnosis and result in more targeted treatments.
Preterm Birth Risk, Preeclampsia Exosome Tests Enter Clinical Validation
NX Prenatal and Indiana University School of Medicine are collaborating to develop exosome blood tests for preterm birth risk and preeclampsia.